Vasoactive agents

被引：3

作者：

Husedzinovic, Ino ^{[1
]}

Bradic, Nikola ^{[1
]}

Goranovic, Tanja ^{[1
]}

机构：

[1] Univ Zagreb, Univ Hosp Dubrava, Dept Anesthesiol Reanimatol & Intens Care Med, Zagreb 10000, Croatia

来源：

SIGNA VITAE | 2006年 / 1卷 / 01期

关键词：

vasoactive agents; inotropic agents; levosimendan; phosphodiesterase III inhibitors;

D O I：

10.22514/SV11.102006.1

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

This article is a short review of vasoactive drugs which are in use in todays clinical practice. In the past century, development of vasoactive drugs went through several phases. All of these drugs are today divided into several groups, depending on their place of action, pharmacological pathways and/or effects on target organ or organ system. Hence, many different agents are today in clinical practice, we have shown comparison between them. These agents provide new directions in the treatment of cardiovascular compromise, suggesting that the primary goal of therapy is to produce a vasodilatory effect of the circulation rather than to reverse hemodynamic failure by using inotropic agents, with their inherent risks and side effects.

引用

收藏

页码：9 / 12

页数：4

相关论文

共 16 条

[1] Levosimendan in off-pump coronary artery bypass - A four-times masked controlled study [J].

Barisin, S ;

Husedzinovic, I ;

Sonicki, Z ;

Bradic, N ;

Barisin, A ;

Tonkovic, D .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 (06) :703-708

[2] Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial [J].

Follath, F ;

Cleland, JGF ;

Just, H ;

Papp, JGY ;

Scholz, H ;

Peuhkurinen, K ;

Harjola, VP ;

Mitrovic, V ;

Abdalla, M ;

Sandell, EP ;

Lehtonen, L .

LANCET, 2002, 360 (9328) :196-202

[3] Vasopressin vs. norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects [J].

Guzman, JA ;

Rosado, AE ;

Kruse, JA .

JOURNAL OF APPLIED PHYSIOLOGY, 2003, 95 (02) :803-809

[4]

Husedzinovic I, 2005, CROAT MED J, V46, P950

[5]

HUSEDZINOVIC I, 2005, INTENSIVE CARE ME S1, V31, pS97

[6] RITZ-5: Randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema - A prospective, multicenter, double-blind, placebo-controlled study [J].

Kaluski, E ;

Kobrin, I ;

Zimlichman, R ;

Marmor, A ;

Krakov, O ;

Milo, O ;

Frey, A ;

Kaplan, S ;

Krakover, R ;

Caspi, A ;

Vered, Z ;

Cotter, G .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (02) :204-210

[7] Pharmacokinetics and pharmacodynamics of intravenous inotropic agents [J].

Lehtonen, LA ;

Antila, S ;

Pentikäinen, PJ .

CLINICAL PHARMACOKINETICS, 2004, 43 (03) :187-203

[8] Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties [J].

Lehtonen, LA .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (05) :955-970

[9] Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction - A randomized, placebo-controlled, double-blind study (RUSSLAN) [J].

Moiseyev, VS ;

Poder, P ;

Andrejevs, N ;

Ruda, MY ;

Golikov, AP ;

Lazebnik, LB ;

Kobalava, ZD ;

Lehtonen, LA ;

Laine, T ;

Nieminen, MS ;

Lie, KI .

EUROPEAN HEART JOURNAL, 2002, 23 (18) :1422-1432

[10]

OPIE LH, 1986, DRUG HEART, P306